Cytokinetics Inc - Asset Resilience Ratio
Cytokinetics Inc (CYTK) has an Asset Resilience Ratio of 53.33% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of Cytokinetics Inc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Cytokinetics Inc's Asset Resilience Ratio has changed over time. See shareholders equity of Cytokinetics Inc for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Cytokinetics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Cytokinetics Inc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $759.70 Million | 53.33% |
| Total Liquid Assets | $759.70 Million | 53.33% |
Asset Resilience Insights
- Very High Liquidity: Cytokinetics Inc maintains exceptional liquid asset reserves at 53.33% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Cytokinetics Inc Industry Peers by Asset Resilience Ratio
Compare Cytokinetics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Cytokinetics Inc (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Cytokinetics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 53.33% | $759.70 Million | $1.42 Billion | -16.67pp |
| 2024-12-31 | 70.00% | $981.16 Million | $1.40 Billion | +9.12pp |
| 2023-12-31 | 60.87% | $501.80 Million | $824.32 Million | -9.78pp |
| 2022-12-31 | 70.66% | $717.00 Million | $1.01 Billion | +27.99pp |
| 2021-12-31 | 42.67% | $358.97 Million | $841.32 Million | -28.72pp |
| 2020-12-31 | 71.39% | $381.07 Million | $533.80 Million | +6.29pp |
| 2019-12-31 | 65.10% | $188.68 Million | $289.81 Million | -8.99pp |
| 2018-12-31 | 74.10% | $156.47 Million | $211.18 Million | +25.36pp |
| 2017-12-31 | 48.74% | $143.69 Million | $294.81 Million | -3.79pp |
| 2016-12-31 | 52.53% | $89.38 Million | $170.14 Million | +12.29pp |
| 2015-12-31 | 40.24% | $46.37 Million | $115.24 Million | -7.15pp |
| 2014-12-31 | 47.39% | $63.01 Million | $132.97 Million | -21.82pp |
| 2013-12-31 | 69.20% | $57.57 Million | $83.19 Million | -6.99pp |
| 2012-12-31 | 76.20% | $59.09 Million | $77.55 Million | +18.99pp |
| 2011-12-31 | 57.21% | $30.19 Million | $52.77 Million | -12.19pp |
| 2010-12-31 | 69.40% | $54.12 Million | $77.99 Million | -3.33pp |
| 2009-12-31 | 72.73% | $89.17 Million | $122.60 Million | +55.52pp |
| 2008-12-31 | 17.21% | $15.05 Million | $87.45 Million | +15.16pp |
| 2007-12-31 | 2.04% | $3.17 Million | $155.37 Million | -39.34pp |
| 2006-12-31 | 41.39% | $70.16 Million | $169.52 Million | -27.17pp |
| 2005-12-31 | 68.55% | $62.70 Million | $91.46 Million | -3.77pp |
| 2004-12-31 | 72.32% | $92.64 Million | $128.10 Million | +33.83pp |
| 2003-12-31 | 38.49% | $24.20 Million | $62.87 Million | +19.93pp |
| 2002-12-31 | 18.56% | $10.43 Million | $56.17 Million | -- |
About Cytokinetics Inc
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral… Read more